Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology
Open Access
- 21 October 2025
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (43)
Abstract
Myasthenia gravis (MG) is an autoimmune disorder caused mainly by autoantibodies against the acetylcholine receptor (AChR), leading to muscle weakness. While treatments targeting AChR autoantibodies benefit many, some patients remain refractory, highlighting the need for personalized therapies. This study evaluates the therapeutic potential of S-1117, a pan-IgG-specific protease, in AChR autoantibody-mediated pathology. Using live cell-based assays, we examined AChR-specific monoclonal IgG autoantibodies (mAbs) and patient-derived serum samples for their effects on receptor binding, blockade, internalization, and complement activation, before and after treatment with S-1117. S-1117 effectively removed the crystallizable fragment (Fc)γ from both mAbs and serum IgG, impairing Fcγ-mediated complement activation in both soluble and antigen-bound forms. In cases with partial complement reduction, AChR-specific IgM contributed to complement deposition. AChR-IgM acted in concert with IgG in some patients to enhance complement deposition, while acting as main complement driver in others. An IgM-specific protease completely suppressed the pathogenic effects of AChR-IgM in two independent patient cohorts. These findings highlight the therapeutic potential of S-1117 in neutralizing AChR-IgG Fcγ-mediated effector functions and reveal an MG subset driven by IgM pathology. Our study shows that targeting both IgG- and IgM-mediated mechanisms with therapeutic proteases provides an approach to MG treatment and establishes a framework for patient stratification based on disease mechanisms, advancing precision medicine in MG.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01-AI114780)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R21-AI164590)
- NIH | Rare Diseases Clinical Research Consortia (U54-NS115054)
This publication has 79 references indexed in Scilit:
- Autoimmune mechanisms elucidated through muscle acetylcholine receptor structuresCell, 2025
- Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathologyActa Neuropathologica, 2023
- Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extensionJournal of Neurology, 2023
- Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificitiesActa Neuropathologica, 2022
- ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumabJournal of Neurology, 2020
- Blocking of experimental arthritis by cleavage of IgG antibodies in vivoArthritis & Rheumatism, 2007
- ?-Bungarotoxin sensitization in experimental autoimmune myasthenia gravisMuscle & Nerve, 1993
- Humoral immunity in myasthenia gravis: Biochemical characterization of acquired antireceptor antibodies and clinical correlationsAnnals of Neurology, 1981
- Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravisJournal of Neuroimmunology, 1981
- The activation mechanism of the alternative pathway of the human complement system by the immune precipitate formed with F(ab′)2 of rabbit IgG antibody: The generation of C3- and C5-cleaving enzymes of the immune precipitateImmunochemistry, 1977